Abstract:Bladder cancer is recognized as one of the most prevalent malignant tumors within the urinary system. The conventional treatment approach for bladder cancer typically involves a combination of surgery, radiotherapy, and chemotherapy. However, the efficacy of current treatment modalities remains suboptimal, prompting ongoing efforts to develop novel and more effective therapeutic strategies to better address the clinical demands of bladder cancer management. In this study, we utilized the orthotopic mouse model to assess the effectiveness of intravesical conventional chemotherapy alone and in combination with immunotherapy for treating bladder cancer. The anti-tumor effect was analyzed by determining bioluminescence imaging (BLI), while histopathological analysis was conducted to evaluate the tumor proliferation and invasion capabilities upon treatment. Additionally, alterations in the immune microenvironment within different treatment methods were studied through flow cytometry for various T-cell markers. BLI and tumor weights analysis revealed that the intravesical route of doxorubicin administration produced better treatment efficacy than the conventional chemotherapy through the intraperitoneal route and combination of doxorubicin and anti-PD-L1 i.p administration. Histopathological analysis and proliferation markers (Ki-67 staining) revealed significant differences across the intravesical, conventional chemotherapy, and immune combination therapy groups. Importantly, intravesical treatment was more effective in reducing tumor cell proliferation compared to the other groups. FACS analysis revealed the route of administration significantly impacted the immune response in the tumor microenvironment. Our results demonstrate that both intravesical and conventional doxorubicin chemotherapy led to a significant decrease in CD8+ T cell expression (p < 0.01), while intravesical treatment exhibited a more pronounced activation of CD8+ T cells, as evidenced by increased CD69 expression. Treg cells also showed moderate reductions in the conventional chemotherapy and immune combination therapy groups. Notably, the intravesical approach activated CD8+ T cells more effectively and reduced the expression of the exhaustion marker PD-1 compared to immune combination therapy. Overall, these findings highlight the potential of intravesical doxorubicin delivery to activate CD8+ T cells and reduce immune exhaustion, enhancing its anti-tumor efficacy. These results suggest that intravesical administration may be a viable treatment option for bladder cancer in clinical settings.

High-dose radiation-induced immunogenic cell death of bladder cancer cells leads to dendritic cell activation

Hypofractionated Radiation Induced the Immunogenic Death of Bladder Cancer Cells Leading to the Immune Sensitization of Dendritic Cells

Inhibitory Effects of a Dendritic Cell Vaccine Loaded with Radiation-Induced Apoptotic Tumor Cells on Tumor Cell Antigens in Mouse Bladder Cancer.

Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer

Inhibitory effects of dendritic cell (DC) vaccine loading antigen with irradiated apoptotic MB49 tumor cells against bladder cancer cells in mice

Irradiation enhances dendritic cell potential antitumor activity by inducing tumor cell expressing TNF-α

Radiation-induced decrease of CD8 + dendritic cells contributes to Th1/Th2 shift

Radiation-induced Decrease of CD8 + Dendritic Cells Contributes to Th1/Th2 Shift

Radiation-induced augmentation in dendritic cell function is mediated by apoptotic bodies/STAT5/Zbtb46 signaling

Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness

Long Term Exposure to Γ‑rays Induces Radioresistance and Enhances the Migration Ability of Bladder Cancer Cells

Radiation-Induced Apoptosis along with Local and Systemic Cytokine Elaboration is Associated with Dc Plus Radiotherapy-Mediated Renal Cell Tumor Regression

Cdc20 induces the radioresistance of bladder cancer cells by targeting FoxO1 degradation

Reduction of Major Histocompatibility Complex Class I Expression on Bladder Carcinoma Following Tumor Antigen‐pulsed Dendritic Cell Vaccine: Implications for Immunoresistance in Therapy

PD1hi CD200hi CD4+ exhausted T cell increase immunotherapy resistance and tumour progression by promoting epithelial–mesenchymal transition in bladder cancer

Exposure to Low-Dose Radiation Enhanced the Antitumor Effect of a Dendritic Cell Vaccine

Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy

A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer

Intravesical Delivery Enhances Anti-Tumor Efficacy by Activating CD8+ T Cells with High CD69 and Low PD-1 Expression in Bladder Cancer.

Effect of Treatment with Local Administration of Dendritic Cells Combination Radiotherapy on the Expression of Bcl-2 and Bax in Renal Tumor Bearing Mice